Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -81% Improvement Relative Risk c19early.org/z Assiri et al. Zinc for COVID-19 ICU PATIENTS Is very late treatment with zinc beneficial for COVID-19? Retrospective 118 patients in Saudi Arabia Higher mortality with zinc (not stat. sig., p=0.44) Assiri et al., J. Infection and Public Health, doi:10.1016/j.jiph.2021.08.030 Favors zinc Favors control
COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study
Assiri et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.030
Assiri et al., COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study, Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.030
Aug 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 118 ICU patients in Saudi Arabia showing no significant differences in unadjusted results with zinc, vitamin D, and favipiravir treatment. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
This study includes favipiravir, zinc, and vitamin D.
risk of death, 80.8% higher, RR 1.81, p = 0.44, treatment 10 of 60 (16.7%), control 4 of 58 (6.9%), inverted to make RR<1 favor treatment, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Assiri et al., 28 Aug 2021, retrospective, Saudi Arabia, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study
Abdullah Assiri, Mir J Iqbal, Atheer Mohammed, Abdulrhman Alsaleh, Ahmed Assiri, Adeeb Noor, Redhwan Nour, Moteb Khobrani
Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.030
Background: The COVID-19 pandemic remains an immediate and present concern, yet as of now there is still no approved therapeutic available for the treatment of COVID-19.This study aimed to investigate and report evidence concerning demographic characteristics and currently-used medications that contribute to the ultimate outcomes of COVID-19 ICU patients. Methods: A retrospective cohort study was conducted among all COVID-19 patients in the Intensive Care Unit (ICU) of Asir Central Hospital in Saudi Arabia between the 1st and 30th of June 2020. Data extracted from patients' medical records included their demographics, home medications, medications used to treat COVID-19, treatment durations, ICU stay, hospital stay, and ultimate outcome (recovery or death).Descriptive statistics and regression modelling were used to analyze and compare the results. The study was approved by the Institutional Ethics Committees at both Asir Central Hospital and King Khalid University. Results: A total of 118 patients with median age of 57 years having definite clinical and disease outcomes were included in the study. Male patients accounted for 87% of the study population, and more than 65% experienced at least one comorbidity. The mean hospital and ICU stay was 11.4 and 9.8 days, respectively. The most common drugs used were tocilizumab (31.4%), triple combination therapy (45.8%), favipiravir (56.8%), dexamethasone (86.7%), and enoxaparin (83%). Treatment with enoxaparin significantly reduced the length of ICU stay (p = 0.04) and was found to be associated with mortality reduction in patients aged 50−75 (p = 0.03), whereas the triple regimen therapy and tocilizumab significantly increased the length of ICU stay in all patients (p = 0.01, p = 0.02 respectively). Conclusion: COVID-19 tends to affect males more significantly than females. The use of enoxaparin is an important part of COVID-19 treatment, especially for those above 50 years of age, while the use of triple combination therapy and tocilizumab in COVID-19 protocols should be reevaluated and restricted to patients who have high likelihood of benefit.
Competing interests None declared. Ethical approval Not required.
References
Ahmad, Alkharfy, Alrabiah, Alhossan, Saudi Arabia, pharmacists and COVID-19 pandemic, J Pharm Policy Pract
Alsofayan, Althunayyan, Khan, Hakawi, Assiri, Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study, J Infect Public Health
Barry, Amri, Memish, COVID-19 in the shadows of MERS-CoV in the Kingdom of Saudi Arabia, J Epidemiol Glob Health
Bergin, Browne, Murray, Interim Guidance for the use of tocilizumab in the management of patients who have severe COVID-19 with suspected hyperinflammation
Chen, Wu, Chen, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ
Garg, Kim, Whitaker, Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states, MMWR Morb Mortal Wkly Rep
Goyal, Choi, Pinheiro, Clinical characteristics of Covid-19 in New York City, N Engl J Med
Hung, Lung, Tso, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet
Hussain, Farhana, Alwutayd, Efficacy of tocilizumab in Covid 19: a metanalysis of case series studies, medRxiv
Jin, Zhan, Peng, Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: an evidence-based clinical practice guideline (updated version), Mil Med Res
Jordan, Adab, Cheng, Covid-19: risk factors for severe disease and death, BMJ
Luo, Liu, Qiu, Liu, Liu et al., Tocilizumab treatment in COVID-19: a single center experience, J Med Virol
Mcmichael, Clark, Pogosjans, COVID-19 in a long-term care facility -King County, Washington, MMWR Morb Mortal Wkly Rep
Pawlowski, Venkatakrishnan, Kirkup, Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients, medRxiv
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost
Tobaiqy, Qashqary, Al-Dahery, Therapeutic management of patients with COVID-19: a systematic review, Infect Prev Pract
Van Singer, Brahier, Ngai, COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department, J Allergy Clin Immunol
Venisse, Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam, Clin Pharmacol
Weiss, Murdoch, Clinical course and mortality risk of severe COVID-19, Lancet
Zhang, Zhang, Wang, Zhu, Wang et al., Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis, Respir Res
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zhou, Zhang, Tian, Xiong, Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus, Ann Palliat Med
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit